BIomarker-dRiven Dosing Interval Extension of biologics in asthma (the BIRDIE trial)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505839-12-01

Enrollment

Registered

2023-09-26

Start date

2024-02-26

Completion date

Unknown

Last updated

2025-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe asthma

Brief summary

The main study endpoint is the number of injections in the mepolizumab and in the dupilumab intervention group compared to the control groups during the follow-up period.

Interventions

DRUGNucala 100 mg powder for solution for injection

DRUGDupixent 100 mg solution for injection in pre-filled syringe

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The main study endpoint is the number of injections in the mepolizumab and in the dupilumab intervention group compared to the control groups during the follow-up period.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026